{"id":"https://genegraph.clinicalgenome.org/r/58ac87e7-9052-42c2-9037-feefc9333576v1.0","type":"EvidenceStrengthAssertion","dc:description":"FANCM was first reported concerning autosomal dominant inheritance and breast cancer susceptibility in 2015 (Peterlongo P, et al., PMID: 26130695). Per criteria outlined by the ClinGen Lumping and Splitting Working Group, we lumped the recessive disorders premature ovarian failure 15 (MONDO:0054862), spermatogenic failure 28 (MONDO:0054732), and FA-like syndrome(MONDO:0009217) and split recessive disorder Fanconi Anemia (MONDO: 0019391) due to substantial differences in phenotype and inheritance pattern from breast cancer risk. The potential increased risk of breast cancer in individuals with heterozygous FANCM variants has been studied over the last decade, and although some studies show an increased risk (33471974, 33471991, 34584094, 36707629), others do not (38063144). \n\nOne variant (FANCM: c.1972C>T) reported in breast cancer patients in one publication (PMID: 31700994) is included in this curation.\nMore evidence is available in the literature (33471974, 33471991, 34584094, 36707629), reported associations between protein-truncating variants or missense variants in FANCM and breast cancer. The mechanism of pathogenicity appears to be loss of function. This gene-disease relationship is also supported by experimental evidence from in vitro functional assays (PMID: ).  The FANCM: c.1972C>T variant results in a truncated protein that lost the binding domains to the FA core, to Bloom´s complex and the FAAP24 protein.\n\nIn summary, limited evidence supports the relationship between FANCM and autosomal dominant inheritance Breast cancer susceptibility. This relationship has been demonstrated in patients with monoallelic pathogenic variants in FANCM (PMIDs: 26130695, 31700994). The ClinGen Hereditary Cancer GCEP approved this classification on the meeting date of November 22, 2024 (SOP Version 11).","dc:isVersionOf":"https://genegraph.clinicalgenome.org/r/58ac87e7-9052-42c2-9037-feefc9333576","GCISnapshot":"https://genegraph.clinicalgenome.org/r/25744c57-8e53-403b-a2ec-fb405ad452cc","calculatedEvidenceStrength":"Limited","contributions":[{"id":"https://genegraph.clinicalgenome.org/r/25744c57-8e53-403b-a2ec-fb405ad452cc_publish_contrib","agent":"https://genegraph.clinicalgenome.org/agent/10023","date":"2024-12-20T16:38:30.386Z","role":"Publisher"},{"agent":"https://genegraph.clinicalgenome.org/agent/10157","role":"SecondaryContributor"},{"id":"https://genegraph.clinicalgenome.org/r/25744c57-8e53-403b-a2ec-fb405ad452cc_contrib","agent":"https://genegraph.clinicalgenome.org/agent/10023","date":"2024-11-22T18:00:00.000Z","role":"Approver"}],"curationReasons":["NewCuration"],"evidence":[{"id":"https://genegraph.clinicalgenome.org/r/25744c57-8e53-403b-a2ec-fb405ad452cc_overall_genetic_evidence_line","type":"EvidenceLine","evidence":[{"id":"https://genegraph.clinicalgenome.org/r/25744c57-8e53-403b-a2ec-fb405ad452cc_cc_el","type":"EvidenceLine","evidence":[{"id":"https://genegraph.clinicalgenome.org/r/098cf8a6-dcdc-41b8-ae39-b55ec5340594","type":"EvidenceLine","dc:description":"This association was only with MVs within functional or binding domains excluding those in the FAAP24 BD and predicted pathogenic by at least one in silico tool","direction":"Supports","evidence":[{"id":"https://genegraph.clinicalgenome.org/r/098cf8a6-dcdc-41b8-ae39-b55ec5340594_cc_evidence_item","type":"Finding","dc:source":"https://pubmed.ncbi.nlm.nih.gov/36707629","rdfs:label":"Figlioli 2023","caseCohort":{"id":"https://genegraph.clinicalgenome.org/r/ffe0d28c-098d-4200-9d23-3449d1ce8669","type":"Cohort","allGenotypedSequenced":2172,"alleleFrequency":0.001841620626151013,"evidence":[{"id":"https://genegraph.clinicalgenome.org/r/098cf8a6-dcdc-41b8-ae39-b55ec5340594_cc_evidence_item"}],"numWithVariant":4,"relatedCondition":{"id":"obo:MONDO_0016419"}},"controlCohort":{"id":"https://genegraph.clinicalgenome.org/r/c01477b3-c1de-4be4-bb23-ae6fb52bde62","type":"Cohort","allGenotypedSequenced":35179,"alleleFrequency":0.002615196566133204,"evidence":[{"id":"https://genegraph.clinicalgenome.org/r/098cf8a6-dcdc-41b8-ae39-b55ec5340594_cc_evidence_item"}],"numWithVariant":92},"lowerConfidenceLimit":1.07,"method":{"id":"cg:SingleVariantAnalysis"},"pValue":0.038,"statisticalSignificanceType":"","statisticalSignificanceValue":3.51,"statisticalSignificanceValueType":"Odds Ratio","upperConfidenceLimit":11}],"specifiedBy":"GeneValidityCaseControlSingleVariantAnalysisCriteria","strengthScore":0.25},{"id":"https://genegraph.clinicalgenome.org/r/ab286f34-9828-4282-9002-28239c37d8cd","type":"EvidenceLine","direction":"Supports","evidence":[{"id":"https://genegraph.clinicalgenome.org/r/ab286f34-9828-4282-9002-28239c37d8cd_cc_evidence_item","type":"Finding","dc:source":"https://pubmed.ncbi.nlm.nih.gov/31700994","rdfs:label":"Figlioli 2019 ER-negative","caseCohort":{"id":"https://genegraph.clinicalgenome.org/r/6ae3a696-bc28-4934-a213-3352c2c21400","type":"Cohort","allGenotypedSequenced":10760,"alleleFrequency":0.0009293680297397769,"detectionMethod":"Genotyping of FANCM:p.Arg658*  truncating variant was conducted using a custom-designed Illumina genotyping array (the “OncoArray”, Illumina, Inc. San Diego, CA, USA) at six independent laboratories. \n","evidence":[{"id":"https://genegraph.clinicalgenome.org/r/ab286f34-9828-4282-9002-28239c37d8cd_cc_evidence_item"}],"numWithVariant":10,"relatedCondition":{"id":"obo:MONDO_0016419"}},"controlCohort":{"id":"https://genegraph.clinicalgenome.org/r/c55fadaa-acb0-4bf3-8747-991beb87b879","type":"Cohort","allGenotypedSequenced":53736,"alleleFrequency":0.000353580467470597,"detectionMethod":"Genotyping of FANCM:p.Arg658*  truncating variant was conducted using a custom-designed Illumina genotyping array (the “OncoArray”, Illumina, Inc. San Diego, CA, USA) at six independent laboratories. ","evidence":[{"id":"https://genegraph.clinicalgenome.org/r/ab286f34-9828-4282-9002-28239c37d8cd_cc_evidence_item"}],"numWithVariant":19},"lowerConfidenceLimit":1.12,"method":{"id":"cg:SingleVariantAnalysis"},"pValue":0.034,"statisticalSignificanceType":"","statisticalSignificanceValue":2.44,"statisticalSignificanceValueType":"Odds Ratio","upperConfidenceLimit":5.34}],"specifiedBy":"GeneValidityCaseControlSingleVariantAnalysisCriteria","strengthScore":0.5},{"id":"https://genegraph.clinicalgenome.org/r/08caea68-66a0-4e22-a709-056a5afdf452","type":"EvidenceLine","direction":"Supports","evidence":[{"id":"https://genegraph.clinicalgenome.org/r/08caea68-66a0-4e22-a709-056a5afdf452_cc_evidence_item","type":"Finding","dc:source":"https://pubmed.ncbi.nlm.nih.gov/26130695","rdfs:label":"Peterlongo et al 2015","caseCohort":{"id":"https://genegraph.clinicalgenome.org/r/ebadea20-6e20-45da-91b3-fd58e85b192e","type":"Cohort","allGenotypedSequenced":8635,"alleleFrequency":0.002084539664157498,"detectionMethod":"Genotype analyses for FANCM: c.5791C>T. For most studies, cases and controls\n were genotyped at coordinating centre (IFOM, Milano) by custom\n TaqMan SNP genotyping assay (Life Technologies) using the\n following primers and probes. Forward primer: 5′-AGCCTGCT\n GACTACCTTAATTGG-3′; reverse primer: 5′-CTTTAGCAAATC\n TGCGGTTTCTTCT-3′; probe 1: 5′-TGAAAAGAATTCGGATTCC-3′;\n probe 2: 5′-TGAAAAGAATTCAGATTCC-3","evidence":[{"id":"https://genegraph.clinicalgenome.org/r/08caea68-66a0-4e22-a709-056a5afdf452_cc_evidence_item"}],"numWithVariant":18,"relatedCondition":{"id":"obo:MONDO_0016419"}},"controlCohort":{"id":"https://genegraph.clinicalgenome.org/r/8bdb362e-b448-4498-a489-71c4411c9342","type":"Cohort","allGenotypedSequenced":6625,"alleleFrequency":0.0007547169811320754,"detectionMethod":"Genotype analyses for FANCM: c.5791C>T. For most studies, cases and controls\n were genotyped at coordinating centre (IFOM, Milano) by custom\n TaqMan SNP genotyping assay (Life Technologies) using the\n following primers and probes. Forward primer: 5′-AGCCTGCT\n GACTACCTTAATTGG-3′; reverse primer: 5′-CTTTAGCAAATC\n TGCGGTTTCTTCT-3′; probe 1: 5′-TGAAAAGAATTCGGATTCC-3′;\n probe 2: 5′-TGAAAAGAATTCAGATTCC-3","evidence":[{"id":"https://genegraph.clinicalgenome.org/r/08caea68-66a0-4e22-a709-056a5afdf452_cc_evidence_item"}],"numWithVariant":5},"lowerConfidenceLimit":1.04,"method":{"id":"cg:SingleVariantAnalysis"},"pValue":0.043,"statisticalSignificanceType":"","statisticalSignificanceValue":3.67,"statisticalSignificanceValueType":"Odds Ratio","upperConfidenceLimit":13}],"specifiedBy":"GeneValidityCaseControlSingleVariantAnalysisCriteria","strengthScore":0.5},{"id":"https://genegraph.clinicalgenome.org/r/a9096f30-9d19-440b-8376-d526e97a899e","type":"EvidenceLine","direction":"Supports","evidence":[{"id":"https://genegraph.clinicalgenome.org/r/a9096f30-9d19-440b-8376-d526e97a899e_cc_evidence_item","type":"Finding","dc:source":"https://pubmed.ncbi.nlm.nih.gov/31700994","rdfs:label":"Fligioli 2019 TNBC","caseCohort":{"id":"https://genegraph.clinicalgenome.org/r/6884c6bb-6c32-4644-bba0-05a67ba15c57","type":"Cohort","allGenotypedSequenced":4801,"alleleFrequency":0.001458029577171423,"detectionMethod":"Genotyping of FANCM:p.Arg658*  truncating variant was conducted using a custom-designed Illumina genotyping array (the “OncoArray”, Illumina, Inc. San Diego, CA, USA) at six independent ","evidence":[{"id":"https://genegraph.clinicalgenome.org/r/a9096f30-9d19-440b-8376-d526e97a899e_cc_evidence_item"}],"numWithVariant":7,"relatedCondition":{"id":"obo:MONDO_0016419"}},"controlCohort":{"id":"https://genegraph.clinicalgenome.org/r/b1e3d017-2e1f-46a4-ac1b-28482e31dcbb","type":"Cohort","allGenotypedSequenced":53736,"alleleFrequency":0.000353580467470597,"detectionMethod":"Genotyping of FANCM:p.Arg658*  truncating variant was conducted using a custom-designed Illumina genotyping array (the “OncoArray”, Illumina, Inc. San Diego, CA, USA) at six independent ","evidence":[{"id":"https://genegraph.clinicalgenome.org/r/a9096f30-9d19-440b-8376-d526e97a899e_cc_evidence_item"}],"numWithVariant":19},"lowerConfidenceLimit":1.56,"method":{"id":"cg:SingleVariantAnalysis"},"pValue":0.009,"statisticalSignificanceType":"","statisticalSignificanceValue":3.79,"statisticalSignificanceValueType":"Odds Ratio","upperConfidenceLimit":9}],"specifiedBy":"GeneValidityCaseControlSingleVariantAnalysisCriteria","strengthScore":0.5},{"id":"https://genegraph.clinicalgenome.org/r/9e54f6c3-354a-493a-990c-d69c9bbae3b6","type":"EvidenceLine","dc:description":" The Risk of Breast Cancer Overall Associated with Protein-Truncating Variants in 34 Genes.","direction":"Supports","evidence":[{"id":"https://genegraph.clinicalgenome.org/r/9e54f6c3-354a-493a-990c-d69c9bbae3b6_cc_evidence_item","type":"Finding","dc:source":"https://pubmed.ncbi.nlm.nih.gov/33471991","rdfs:label":"BRIDGES study","caseCohort":{"id":"https://genegraph.clinicalgenome.org/r/0812387b-dafd-427c-bbb7-623211eb63ef","type":"Cohort","allGenotypedSequenced":48826,"alleleFrequency":0.006185229181173964,"detectionMethod":"The samples were analyzed a panel of 34 known or suspected  breast cancer susceptibility genes ","evidence":[{"id":"https://genegraph.clinicalgenome.org/r/9e54f6c3-354a-493a-990c-d69c9bbae3b6_cc_evidence_item"}],"numWithVariant":302,"relatedCondition":{"id":"obo:MONDO_0016419"}},"controlCohort":{"id":"https://genegraph.clinicalgenome.org/r/aa8a2bde-35ab-4b95-b89e-c24539e5bf81","type":"Cohort","allGenotypedSequenced":50703,"alleleFrequency":0.005916809656233359,"detectionMethod":"The samples were analyzed a panel of 34 known or suspected  breast cancer susceptibility genes ","evidence":[{"id":"https://genegraph.clinicalgenome.org/r/9e54f6c3-354a-493a-990c-d69c9bbae3b6_cc_evidence_item"}],"numWithVariant":300},"lowerConfidenceLimit":0.9,"method":{"id":"cg:SingleVariantAnalysis"},"pValue":0.48,"statisticalSignificanceType":"","statisticalSignificanceValue":1.06,"statisticalSignificanceValueType":"Odds Ratio","upperConfidenceLimit":1.26}],"specifiedBy":"GeneValidityCaseControlSingleVariantAnalysisCriteria","strengthScore":0.25}],"specifiedBy":"GeneValidityOverallCaseControlEvidenceCriteria","strengthScore":2}],"specifiedBy":"GeneValidityOverallGeneticEvidenceCriteria","strengthScore":2},{"id":"https://genegraph.clinicalgenome.org/r/25744c57-8e53-403b-a2ec-fb405ad452cc_experimental_evidence_line","type":"EvidenceLine","evidence":[{"id":"https://genegraph.clinicalgenome.org/r/25744c57-8e53-403b-a2ec-fb405ad452cc_functional_alteration_evidence_line","type":"EvidenceLine","evidence":[{"id":"https://genegraph.clinicalgenome.org/r/d15a3a2b-39bc-4c77-ab6e-349b04f453e7","type":"EvidenceLine","calculatedScore":1,"direction":"Supports","evidence":[{"id":"https://genegraph.clinicalgenome.org/r/50746d45-24a8-44c3-88e0-5b6f58c6fa37","type":"FunctionalAlteration","dc:description":"In the DEB sensitivity-based assay (Fig. 1c), the EGF280 patient\nderived cell line showed a high-sensitivity phenotype, that was\n rescued by expression of the wt FANCM. EGF280 cells expressing\n FANCM:p.Arg658* failed to rescue DEB sensitivity and showed\n survival rates overlapping with those of the native EGF280 cells. ","dc:source":"https://pubmed.ncbi.nlm.nih.gov/31700994","rdfs:label":"Functional studies of the FANCM:p.Arg658* truncating variant"}],"specifiedBy":"GeneValidityPatientCellFunctionalAlterationCriteria","strengthScore":1}],"specifiedBy":"GeneValidityOverallFunctionalAlterationEvidenceCriteria","strengthScore":1}],"specifiedBy":"GeneValidityOverallExperimentalEvidenceCriteria","strengthScore":1}],"evidenceStrength":"Limited","sequence":9579,"specifiedBy":"GeneValidityCriteria11","strengthScore":3,"subject":{"id":"https://genegraph.clinicalgenome.org/r/dkSUmqAQ5gw","type":"GeneValidityProposition","disease":"obo:MONDO_0016419","gene":"hgnc:23168","modeOfInheritance":"obo:HP_0000006"},"version":"1.0","websiteLegacyID":"https://genegraph.clinicalgenome.org/r/assertion_25744c57-8e53-403b-a2ec-fb405ad452cc-","@context":{"@vocab":"https://genegraph.clinicalgenome.org/terms/","id":"@id","type":"@type","cg":"https://genegraph.clinicalgenome.org/terms/","dc":"http://purl.org/dc/terms/","obo":"http://purl.obolibrary.org/obo/","hgnc":"https://identifiers.org/hgnc:","rdfs":"http://www.w3.org/2000/01/rdf-schema#","cggv":"https://genegraph.clinicalgenome.org/r/gci/","evidenceStrength":{"@type":"@vocab"},"calculatedEvidenceStrength":{"@type":"@vocab"},"computedEvidenceStrength":{"@type":"@vocab"},"specifiedBy":{"@type":"@vocab"},"evidence":{"@container":"@set"},"disease":{"@type":"@vocab"},"gene":{"@type":"@vocab"},"phenotypes":{"@type":"@id"},"agent":{"@type":"@id"},"role":{"@type":"@vocab"},"modeOfInheritance":{"@type":"@vocab"},"sex":{"@type":"@vocab"},"direction":{"@type":"@vocab"},"ageType":{"@type":"@vocab"},"ageUnit":{"@type":"@vocab"},"dc:source":{"@type":"@id"},"curationReasons":{"@type":"@vocab","@container":"@set"},"GCISnapshot":{"@type":"@id"},"dc:isVersionOf":{"@type":"@id"},"websiteLegacyID":{"@type":"@id"}}}